|
|
|
|
|
Teisinis statusas
Patentas neįsigaliojo (pagal EPK)
| (51) | INT.CL. | A61K 31/4035 | |
| A61P 35/00 | |||
| C07K 16/28 | |||
| A61K 39/395 |
| (11) | Patento numeris | 2301535 |
| (13) | Dokumento rūšis | T |
| (96) | Europos patento paraiškos numeris | 11151126.7 |
| Europos patento paraiškos padavimo data | 2006-08-31 | |
| (97) | Europos patento paraiškos paskelbimo data | 2011-03-30 |
| (45) | Paskelbimo apie Europos patento išdavimą data | 2014-05-28 |
| (46) | Apibrėžties vertimo paskelbimo data |
| (30) | Numeris | Data | Šalis |
| 712823 P | 2005-09-01 | US |
| (72) |
Bartlett, Justin B., US
Muller, George W., US
Schafer, Peter H., US
Galustian, Christine, GB
Dalgleish, Angus C., GB
Meyer, Brendan, GB
|
| (73) |
Celgene Corporation,
86 Morris Avenue, Summit New Jersey 07901,
US
|
| (54) | Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |
| Immunological uses of immunomodulatory compounds for vaccine and anti-infectious disease therapy |